FDA sets new potency expectations for cell and gene therapy products
The U.S. Food and Drug Administration has issued final guidance aimed at tightening how manufacturers of cell and gene therapy products demonstrate potency before those products reach patients. The document replaces the agency’s 2011 guidance and is designed to give developers a science-based, risk-based framework for proving that each batch does what it is intended to do therapeutically.
For therapies built for cancer, rare disease, and other serious conditions, potency is not an abstract regulatory concept. It is the practical bridge between a complex living product and the biological effect a patient depends on. A therapy can clear manufacturing hurdles and still fail at the bedside if its functional activity is not measured, controlled, and maintained through production and distribution.
Karim Mikhail, B. Pharm., M.S., director of the Center for Biologics Evaluation and Research, tied the guidance directly to patient need and product reliability. The message is blunt: patients receiving these products deserve confidence that what is infused, injected, or delivered will behave as intended.
Potency assurance moves from one-time testing to a lifecycle strategy
The guidance directs manufacturers to build a Potency Assurance Strategy that begins early and continues through commercialization and post-approval monitoring. In regulatory terms, that means potency is no longer treated as a single release test layered onto the end of development. It becomes a lifecycle requirement, embedded in the way the product is designed, manufactured, and verified over time.
The framework applies from early-phase investigational new drug submissions through biologics license application review and into continued post-market verification. Manufacturers are expected to use a comprehensive plan that reflects the product’s biology, its manufacturing risks, and the clinical context in which it will be used. For some therapies, especially those made individually for one patient, the margin for error is narrow. Short shelf life, highly variable raw materials, and complex manufacturing steps can all affect whether the final product remains biologically active.
One sentence captures the operational burden: every batch must be shown to meet a defined standard of potency before it reaches a patient.
Variability, bioactivity, and the manufacturing bottleneck
The guidance places special emphasis on controls for variability in raw materials, testing during manufacturing, and lab assays that confirm biologic activity matches the product’s intended therapeutic effect. In a field where living cells and viral vectors can change across production runs, those controls are not cosmetic. They are the only way to reduce drift between what was designed in development and what actually arrives in clinic.
Products with short shelf lives and patient-specific manufacturing raise the stakes further. Unlike conventional drugs that can be produced in large, stable lots, many CGT products are customized or time-sensitive. A potency framework has to account for that reality without forcing developers into a one-size-fits-all model that ignores how these therapies are actually made.
The guidance also addresses viral vector gene therapies, a category where potency can hinge on complex relationships between vector design, transduction efficiency, and the ultimate biological response. When the therapeutic effect depends on a chain of molecular events rather than a simple receptor interaction, potency testing has to reflect more than concentration alone. It has to capture functional performance.
Regulatory clarity is meant to speed development without weakening standards
The agency framed the final guidance as a way to support faster access to safe and effective therapies while preserving rigorous quality expectations. That balance matters because many CGT recipients have limited or no alternative treatment options. In this setting, delays caused by unclear potency requirements can slow development just as surely as scientific failure can.
Clearer expectations can also reduce regulatory ambiguity for sponsors deciding how to structure assay development, manufacturing controls, and post-approval monitoring plans. A predictable pathway is especially important for smaller developers and programs working with highly individualized products, where uncertainty can consume time, capital, and manufacturing capacity.
At the same time, the document reinforces a central regulatory principle: approval is not the end of the potency conversation. Continued post-market verification is part of the standard, because product performance can shift as manufacturing scales, suppliers change, or real-world use expands beyond the original trial population.
Post-approval monitoring is now part of the quality equation
For patients, the significance of this guidance is straightforward. A therapy that cannot reliably demonstrate potency is not a finished medicine, no matter how advanced the science behind it may be.
That reality is especially important in cell and gene therapy, where a product may be personalized, fragile, and expensive to make. If potency slips, the consequences may include reduced clinical effect, inconsistent outcomes, or avoidable risk to patients who have already exhausted standard treatment options. The FDA’s approach treats potency as a core attribute of quality rather than an afterthought added during review.
The agency plans to host a webinar on December 10, 2026, to help stakeholders understand and implement the guidance. For manufacturers, regulators, and clinical developers, the practical task now is to translate this framework into assays, controls, and release criteria that can stand up to scrutiny across the full product lifecycle.
What remains unresolved is how quickly the industry will standardize potency strategies across such a diverse group of products, especially when assay development, manufacturing platforms, and clinical indications vary so widely from one program to the next.